PureTech Health (PureTech Health) ROCE % : -4.31% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PureTech Health's annualized ROCE % for the quarter that ended in Dec. 2023 was -4.31%.

PureTech Health ROCE % Historical Data

The historical data trend for PureTech Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health ROCE % Chart

PureTech Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

98.39

2.72

-7.09

-13.40

-3.62

PureTech Health Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															10.83	-15.51	-10.90	-2.80	-4.31

PureTech Health ROCE % Calculation

PureTech Health's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-22.615	/	( ( (702.647 - 96.885)	+	(693.973 - 51.37) )	/ 2 )
	=	-22.615	/	( (605.762	+	642.603)	/ 2 )
	=	-22.615	/	624.1825
	=	-3.62 %

PureTech Health's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-27.718	/	( ( (693.552 - 49.265)	+	(693.973 - 51.37) )	/ 2 )
	=	-27.718	/	( ( 644.287	+	642.603 )	/ 2 )
	=	-27.718	/	643.445
	=	-4.31 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

PureTech Health (OTCPK:PTCHF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PureTech Health ROCE % Related Terms

Thank you for viewing the detailed overview of PureTech Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health (PureTech Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (OTCPK:PTCHF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PRTC:USA PRTCl:UK PRTC:UK PRTCL:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.